As per the research report, the size of the Europe Overactive Bladder Treatment Market is valued at USD 0.96 billion in 2021 and is projected to grow at a CAGR of 3.2%, to reach USD 1.12 billion by 2026 during the forecast 2021 to 2026.
Overactive bladder is the condition in which the person has an urge to urinate frequently. Over time, this might lead to the loss of bladder control and this condition is called urge incontinence. People generally neglect this condition for years before it becomes a severe inconvenience.
The actual causes of this condition are not known. Initial treatment of this condition generally includes bladder training, pelvic floor exercises and behavioral methods. Medications and neurostimulations are recommended if other methods do not work. Also, there are procedures that use medical devices such as Urgent PC Neuromodulation System, injectables and surgical interventions are used for people with neurological conditions.
Due to the increasing number of people with neurological diseases, especially among the geriatric population, the demand for overactive bladder treatment has increased. The availability of innovative therapies and increasing pharmaceutical companies are driving the market growth. However, lack of awareness about the condition as well as the treatments available and side effects associated with the usage of drugs are hindering the market growth.
This research report segmented and sub-segmented into the following categories:
On the basis of region, the Europe Overactive Bladder Treatment market is segmented into N UK, Spain, Italy, Germany, and France. Europe region has the second-highest market share next only to North America and is expected to retain this position during the forecast period.
Key players operating in the Europe Overactive Bladder Treatment Market profiled in this report are Pfizer, Allergan Plc, Hisamitsu Pharmaceutical, Johnson & Johnson, Astellas Pharma Inc, Teva Pharmaceutical Industries, Mylan N.V, Sanofi, Aurobindo Pharma Ltd, and Endo International.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Treatment
5.1.1 Introduction
5.1.2 Mirabegron
5.1.3 Anticholinergics
5.1.3.1 Solifenacin
5.1.3.2 Fesoterodine
5.1.3.3 Tolterodine
5.1.3.4 Oxybutynin
5.1.3.5 Darifenacin
5.1.3.6 Trospium
5.1.3.7 Other Anticholinergics
5.1.4 Botox
5.1.5 Intravesical Instillation
5.1.6 Neurostimulation
5.1.7 Y-o-Y Growth Analysis, By Treatment
5.1.8 Market Attractiveness Analysis, By Treatment
5.1.9 Market Share Analysis, By Treatment
5.2 Disease
5.2.1 Introduction
5.2.2 Neurogenic Overactive Bladder
5.2.2.1 Stroke
5.2.2.2 Spinal Cord Injury
5.2.2.3 Parkinson's disease
5.2.2.4 Multiple Sclerosis
5.2.2.5 Other Disorders
5.2.3 Idiopathic Overactive Bladder
5.2.4 Y-o-Y Growth Analysis, By Disease
5.2.5 Market Attractiveness Analysis, By Disease
5.2.6 Market Share Analysis, By Disease
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Treatment
6.1.3.3 By Disease
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Treatment
6.1.4.3 By Disease
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Treatment
6.1.5.3 By Disease
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Pfizer
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Allergan Plc
8.3 Hisamitsu Pharmaceutical
8.4 Johnson & Johnson
8.5 Astellas Pharma Inc
8.6 Teva Pharmaceutical Industries
8.7 Mylan N.V
8.8 Sanofi
8.9 Aurobindo Pharma Ltd
8.10 Endo International
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
